Skip to main content

Table 4 2-year and 5-year rates of bRFS and DMFS

From: Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Sub-group 2-year rate (%) 95% CI 5-year rate (%) 95% CI
bRFS
 FHR 91.6 87.7–95.5 69.2 61.9–76.5
 UHR 78.8 70.0–87.6 66.2 54.6–77.8
vHigh Risk 79.4 72.0–86.8 58.2 48.8–67.6
DMFS
 FHR 96.5 94.0–99.0 88.0 83.1–92.9
 UHR 93.0 87.5–98.5 81.2 71.6–90.8
vHigh risk 93.2 88.7–97.7 78.4 70.8–86.0
  1. Abbreviations: bRFS biochemical relapse-free survival, CI confidence interval, DMFS distant metastases-free survival